<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01950819</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001A2433</org_study_id>
    <secondary_id>2013-000322-66</secondary_id>
    <nct_id>NCT01950819</nct_id>
    <nct_alias>NCT02316938</nct_alias>
  </id_info>
  <brief_title>Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)</brief_title>
  <acronym>TRANSFORM</acronym>
  <official_title>A 24 Month, Multicenter, Randomized, Open-label Safety and Efficacy Study of Concentration-controlled Everolimus With Reduced Calcineurin Inhibitor vs Mycophenolate With Standard Calcineurin Inhibitor in de Novo Renal Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 2-year, randomized, multicenter, open-label, 2-arm study evaluating the graft
      function of everolimus and reduced CNI versus MPA and standard CNI in adult de novo renal
      transplant recipients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 3, 2013</start_date>
  <completion_date type="Actual">January 17, 2018</completion_date>
  <primary_completion_date type="Actual">February 1, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open-label study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Failure on the Composite of Treated Biopsy-proven Acute Rejection (tBPAR) or Estimated Glomerular Filtration Rate (eGFR) &lt; 50 mL/Min/1.73m2.</measure>
    <time_frame>Month 12 is Primary, Month 24 secondary</time_frame>
    <description>Incidence of failure on the composite of treated biopsy-proven acute rejection (tBPAR) or estimated glomerular filtration rate (eGFR) &lt; 50 mL/min/1.73m2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Failure on the Composite of (Treated Biopsy Proven Acute Rejection (tBPAR), Graft Loss or Death</measure>
    <time_frame>Month 12 and 24</time_frame>
    <description>Incidence of failure on the composite of (treated biopsy proven acute rejection (tBPAR), graft loss or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Failure on the Composite Endpoint of tBPAR, Graft Loss, Death or eGFR &lt; 50 mL/Min/1.73m2</measure>
    <time_frame>Month 12 and 24</time_frame>
    <description>Incidence of failure on the composite endpoint of tBPAR, graft loss, death or eGFR &lt; 50 mL/min/1.73m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Failure on the Composite Endpoint of Graft Loss or Death.</measure>
    <time_frame>Month 12 and 24</time_frame>
    <description>Incidence of failure on the composite endpoint of graft loss or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Death, Graft Loss, tBPAR, BPAR, tAR, AR and Humoral Rejection</measure>
    <time_frame>Month 12 and 24</time_frame>
    <description>Incidence of death, graft loss, tBPAR (treated biopsy proven acute rejection), BPAR (biopsy proven acute rejection), tAR (treated acute rejection), AR (acute rejection) and humoral rejection (aAMR : active antibody mediated rejection and cAMR: chronic antibody mediated rejection)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of eGFR &lt; 50 mL/Min/1.73m2</measure>
    <time_frame>Month 12 and 24</time_frame>
    <description>Incidence of eGFR &lt; 50 mL/min/1.73m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Allograft Function : Mean Estimated Glomerular Filtration Rate, eGFR</measure>
    <time_frame>Baseline (week 4), Month 12 and 24</time_frame>
    <description>Renal allograft function : mean estimated glomerular filtration rate, eGFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of Renal Function, as eGFR, Over Time by Slope Analysis.</measure>
    <time_frame>Month 12 and 24</time_frame>
    <description>Rate of change of renal function, as eGFR, calculated using MDRD4 formula (Coresh, 2003) and adjusted by covariates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Function Assessed by Creatinine Lab Values</measure>
    <time_frame>Month 12 and 24</time_frame>
    <description>Mean Renal function as assessed in clinical practice, by ceatinine values. Analysis is done without considering missing values for analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Function by Alternative Formulae (e.g. CKD-EPI). eGFR Values Reported</measure>
    <time_frame>Month 12 and 24</time_frame>
    <description>Mean Renal function as used in clinical practice, using different formula for calculation of renal function than MDRD4 (our primary efficacy parameter), and other alternate formulae (e.g. CKD-EPI). Analysis is done without considering missing values for analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events, Serious Adverse Events and Adverse Events Leading to Study Regimen Discontinuation.</measure>
    <time_frame>Month 24</time_frame>
    <description>Incidence of adverse events, serious adverse events and adverse events leading to study regimen discontinuation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Cytomegalovirus and BK Virus, New Onset Diabetes Mellitus, Chronic Kidney Disease With Associated Proteinuria and Calcineurin Inhibitor Associated Adverse Events.</measure>
    <time_frame>Month 24</time_frame>
    <description>Incidence of cytomegalovirus and BK virus, new onset diabetes mellitus, chronic kidney disease with associated proteinuria and calcineurin inhibitor associated adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Protein and Albumin Excretion by Treatment Estimated by Urinary Protein/Creatinine and Urinary Albumin/Creatinine Ratios.</measure>
    <time_frame>Baseline, Month 12 and 24</time_frame>
    <description>Mean urinary protein and albumin excretion by treatment estimated by mean urinary protein/creatinine and urinary albumin/creatinine ratios.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Major Cardiovascular Events.</measure>
    <time_frame>Month 24</time_frame>
    <description>Incidence of major cardiovascular events by Preferred Term</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Malignancies.</measure>
    <time_frame>Month 24</time_frame>
    <description>Incidence of malignancies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Failure on the Composite of Treated Biopsy-proven Acute Rejection (tBPAR) or Estimated Glomerular Filtration Rate (eGFR) &lt; 50 mL/Min/1.73m2 Among Compliant Subjects.</measure>
    <time_frame>Month 12 and 24</time_frame>
    <description>Incidence of failure on the composite of treated biopsy-proven acute rejection (tBPAR) or estimated glomerular filtration rate (eGFR) &lt; 50 mL/min/1.73m2 among compliant subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence tBPAR (Treated Biopsy-proven Acute Rejection) by Severity and Time to Event (Participants)</measure>
    <time_frame>Month 12 and 24</time_frame>
    <description>Incidence tBPAR, defined as any condition where the subject received anti-rejection treatment and was histologically diagnosed as acute rejection (according to the Banff 2009 criteria), by severity (grade IA, IB, IIA, IIB, III) and time to event. Grades for T-cell mediated rejection, with increasing severity:
Type IA - Significant interstitial infiltration (&gt; 25% of parenchyma) and foci of moderate tubulitis (&gt; 4 mononuclear cells/tubular cross section or group of 10 tubular cells).
Type IB - Significant interstitial infiltration (&gt; 25% of parenchyma) and foci of severe tubulitis (&gt; 10 mononuclear cells/tubular cross section or group of 10 tubular cells).
Type IIA - Mild to moderate intimal arteritis
Type IIB - Severe intimal arteritis comprising &gt; 25% of the lumenal area
Type III - Transmural (full vessel wall thickness) arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells (with accompanying lymphocytic inflammation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence tBPAR (Treated Biopsy-proven Acute Rejection) by Severity and Time to Event (Events)</measure>
    <time_frame>Month 12 and 24</time_frame>
    <description>Incidence tBPAR, defined as any condition where the subject received anti-rejection treatment and was histologically diagnosed as acute rejection (according to the Banff 2009 criteria), by severity (grade IA, IB, IIA, IIB, III) and time to event. Grades for T-cell mediated rejection, with increasing severity:
Type IA - Significant interstitial infiltration (&gt; 25% of parenchyma) and foci of moderate tubulitis (&gt; 4 mononuclear cells/tubular cross section or group of 10 tubular cells).
Type IB - Significant interstitial infiltration (&gt; 25% of parenchyma) and foci of severe tubulitis (&gt; 10 mononuclear cells/tubular cross section or group of 10 tubular cells).
Type IIA - Mild to moderate intimal arteritis
Type IIB - Severe intimal arteritis comprising &gt; 25% of the lumenal area
Type III - Transmural (full vessel wall thickness) arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells (with accompanying lymphocytic inflammation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of tBPAR (Treated Biopsy-proven Acute Rejection) Excluding Grade IA Rejections</measure>
    <time_frame>Month 12 and 24</time_frame>
    <description>Incidence of tBPAR, defined as any condition where the subject received anti-rejection treatment and was histologically diagnosed as acute rejection (according to the Banff 2009 criteria), excluding grade IA rejections. Grades for T-cell mediated rejection, with increasing severity:
Type IA - Significant interstitial infiltration (&gt; 25% of parenchyma) and foci of moderate tubulitis (&gt; 4 mononuclear cells/tubular cross section or group of 10 tubular cells).
Type IB - Significant interstitial infiltration (&gt; 25% of parenchyma) and foci of severe tubulitis (&gt; 10 mononuclear cells/tubular cross section or group of 10 tubular cells).
Type IIA - Mild to moderate intimal arteritis
Type IIB - Severe intimal arteritis comprising &gt; 25% of the lumenal area
Type III - Transmural (full vessel wall thickness) arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells (with accompanying lymphocytic inflammation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Composite of tBPAR (Treated Biopsy-proven Acute Rejection)or eGRF&lt;50 mL/Min/1.73m2 by Subgroup</measure>
    <time_frame>Month 12 and 24</time_frame>
    <description>Incidence of composite of tBPAR or eGRF&lt;50 mL/min/1.73m2 by subgroup</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of tBPAR (Excluding Grade IA Rejections) or GFR&lt;50 mL/Min/1.73m2</measure>
    <time_frame>Month 12 and 24</time_frame>
    <description>Incidence of tBPAR (excluding grade IA rejections) or GFR&lt;50 mL/min/1.73m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Failure on the Composite of (Treated Biopsy Proven Acute Rejection (tBPAR), Graft Loss or Death or Loss to Follow-up</measure>
    <time_frame>Month 12 and 24</time_frame>
    <description>Incidence of failure on the composite of (treated biopsy proven acute rejection (tBPAR), graft loss or death or loss to follow-up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2037</enrollment>
  <condition>End Stage Renal Disease (ESRD)</condition>
  <condition>Chronic Kidney Disease (CKD)</condition>
  <condition>Hemodialysis</condition>
  <condition>Renal Replacement Therapy</condition>
  <condition>Renal Transplantation</condition>
  <arm_group>
    <arm_group_label>EVR+rCNI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MPA+sCNI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Induction therapy</intervention_name>
    <description>All subjects received induction therapy with basiliximab or rabbit anti-thymocyte globulin, in the peritransplant period.</description>
    <arm_group_label>EVR+rCNI</arm_group_label>
    <arm_group_label>MPA+sCNI</arm_group_label>
    <other_name>Simulect, basiliximab, rATG, Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroids</intervention_name>
    <description>All subjects received maintenance therapy with corticosteroids throughout the 24 month study period. A minimum dose of 5 mg prednisone, or equivalent, per day was maintained.</description>
    <arm_group_label>EVR+rCNI</arm_group_label>
    <arm_group_label>MPA+sCNI</arm_group_label>
    <other_name>prednisone, methylprednisone, methylprednisolone, etc.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EVR+rCNI</intervention_name>
    <description>Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)</description>
    <arm_group_label>EVR+rCNI</arm_group_label>
    <other_name>Zortress, Certican, Neoral, Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MPA+sCNI</intervention_name>
    <description>Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).</description>
    <arm_group_label>MPA+sCNI</arm_group_label>
    <other_name>Myfortic, Cellcept, Neoral, Prograf</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent obtained.

          2. Subject randomized within 24 hr of completion of transplant surgery.

          3. Recipient of a kidney with a cold ischemia time &lt; 30 hours.

          4. Recipient of a primary (or secondary, if first graft is not lost due to immunological
             reasons) renal transplant from a deceased heart beating, living unrelated, living
             related non-human leukocyte antigen identical or an expanded criteria donor.

        Exclusion Criteria:

          1. Subject unable to tolerate oral medication at time of randomization.

          2. Use of other investigational drugs at the time of enrollment.

          3. History of hypersensitivity to any of the study drugs or to drugs of similar chemical
             classes.

          4. Multi-organ transplant recipient.

          5. Recipient of ABO incompatible allograft or complement-dependent lymphocytotoxic (CDC)
             crossmatch positive transplant.

          6. Subject at high immunological risk for rejection as determined by local practice for
             assessment of anti-donor reactivity e.g. high PRA, presence of pre-existing DSA.

          7. Subject who is HIV-positive.

          8. HBsAg and/or a HCV positive subject with evidence of elevated LFTs (ALT/AST levels ≥
             2.5 times ULN). Viral serology results obtained within 6 months prior to randomization
             are acceptable.

          9. Recipient of a kidney from a donor who tests positive for human immunodeficiency virus
             (HIV), hepatitis B surface antigen (HBsAg) or anti-hepatitis C virus (HCV).

         10. Subject with a BMI greater than 35.

         11. Subject with severe systemic infections, current or within the two weeks prior to
             randomization.

         12. Subject requiring systemic anticoagulation.

         13. History of malignancy of any organ system.

         14. Subject with severe restrictive or obstructive pulmonary disorders.

         15. Subject with severe hypercholesterolemia or hypertriglyceridemia that cannot be
             controlled.

         16. Subject with white blood cell (WBC) count ≤ 2,000 /mm3 or with platelet count ≤ 50,000
             /mm3.

         17. Pregnant or nursing (lactating) women.

         18. Women of child-bearing potential, defined as all women physiologically capable of
             becoming pregnant, unless they are using effective methods of contraception during
             dosing of study treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817-1460</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Livingston</city>
        <state>New Jersey</state>
        <zip>07039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17105-8700</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212-3139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2400</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1181ACH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Martin</city>
        <state>Buenos Aires</state>
        <zip>C1107BEA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>W3400ABH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <zip>X5016KEH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <zip>X5016KET</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Corrientes</city>
        <zip>W3400</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santa Fe</city>
        <zip>S3000EPV</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Innsbruck</city>
        <state>Tyrol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Linz</city>
        <zip>A-4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edegem</city>
        <state>Antwerpen</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90020-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05403 000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>04038-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <state>BGR</state>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago</city>
        <zip>8207257</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cali</city>
        <state>Valle Del Cauca</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rijeka</city>
        <zip>51000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zagreb</city>
        <zip>1000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 4</city>
        <zip>140 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mansoura</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nice</city>
        <state>Cedex1</state>
        <zip>06001</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tours Cedex 9</city>
        <state>Indre Et Loire</state>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris cedex 15</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Regensburg</city>
        <state>Bavaria</state>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover Muenden</city>
        <zip>34346</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaiserslautern</city>
        <zip>67655</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln</city>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Thessaloniki</city>
        <state>GR</state>
        <zip>546 42</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <zip>106 76</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Patras</city>
        <zip>265 00</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110 017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560 055</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400 016</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vellore</city>
        <state>Tamil Nadu</state>
        <zip>632004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Parma</city>
        <state>PR</state>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Siena</city>
        <state>SI</state>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya-city</city>
        <state>Aichi</state>
        <zip>466-8650</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toyoake city</city>
        <state>Aichi</state>
        <zip>470 1192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chiba-city</city>
        <state>Chiba</state>
        <zip>260-8712</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kuwait</city>
        <country>Kuwait</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ashrafieh</city>
        <zip>166830</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saida</city>
        <zip>652</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saida</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50589</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Selangor Darul Ehsan</city>
        <zip>68100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44610</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Maastricht</city>
        <state>AZ</state>
        <zip>5800</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Utrecht</city>
        <state>The Netherlands</state>
        <zip>3508 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1101</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szczecin</city>
        <state>Pomorskie</state>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80 952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-355</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-479</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Carnaxide</city>
        <state>Lisboa</state>
        <zip>2790-134</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coimbra</city>
        <zip>3000 075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1600190</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lisbon</city>
        <zip>1069-166</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto</city>
        <zip>4200 319</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620109</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Krasnodar</city>
        <zip>350086</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>123182</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>129010</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nizhnii Novgorod</city>
        <zip>603000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Volzhskiy</city>
        <zip>404120</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dammam</city>
        <zip>15215</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jeddah</city>
        <zip>21499</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riyadh</city>
        <zip>11159</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nis</city>
        <zip>18000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Novi Sad</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Banská Bystrica</city>
        <zip>97517</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <zip>833 05</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kosice</city>
        <zip>04166</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Martin</city>
        <zip>03659</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cape Town</city>
        <state>Western Province</state>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Granada</city>
        <state>Andalucia</state>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Laguna</city>
        <state>Santa Cruz De Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Göteborg</city>
        <zip>SE-413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tainan</city>
        <state>Taiwan ROC</state>
        <zip>70421</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ratchathewi</city>
        <state>Bangkok</state>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Antalya</city>
        <zip>07070</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mecidiyekoy/Istanbul</city>
        <zip>34394</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>Egypt</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Kuwait</country>
    <country>Lebanon</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Saudi Arabia</country>
    <country>Serbia</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>Slovenia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Dominican Republic</country>
    <country>Indonesia</country>
    <country>Jordan</country>
  </removed_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>August 20, 2013</study_first_submitted>
  <study_first_submitted_qc>September 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2013</study_first_posted>
  <results_first_submitted>October 3, 2018</results_first_submitted>
  <results_first_submitted_qc>January 9, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 30, 2019</results_first_posted>
  <disposition_first_submitted>December 1, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>December 1, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">December 7, 2017</disposition_first_posted>
  <last_update_submitted>January 9, 2019</last_update_submitted>
  <last_update_submitted_qc>January 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>kidney failure</keyword>
  <keyword>dialysis</keyword>
  <keyword>renal failure</keyword>
  <keyword>transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Basiliximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydata request.com</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 14, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/19/NCT01950819/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/19/NCT01950819/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The full analysis set consisted of all randomized and transplanted patients. The safet set consisted of all patients who received at least one dose of study drug</recruitment_details>
      <pre_assignment_details>2226 patients screened; 2037 patients transplanted and randomized to treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>EVR+rCNI</title>
          <description>Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)</description>
        </group>
        <group group_id="P2">
          <title>MPA+sCNI</title>
          <description>Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1022"/>
                <participants group_id="P2" count="1015"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="893"/>
                <participants group_id="P2" count="881"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="129"/>
                <participants group_id="P2" count="134"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Graft Loss</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject / Gardian decision</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>technical problems</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis set</population>
      <group_list>
        <group group_id="B1">
          <title>EVR+rCNI</title>
          <description>Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)</description>
        </group>
        <group group_id="B2">
          <title>MPA+sCNI</title>
          <description>Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1022"/>
            <count group_id="B2" value="1015"/>
            <count group_id="B3" value="2037"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>full analysis set</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.79" spread="14.123"/>
                    <measurement group_id="B2" value="48.75" spread="14.515"/>
                    <measurement group_id="B3" value="48.77" spread="14.316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>full analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="312"/>
                    <measurement group_id="B2" value="308"/>
                    <measurement group_id="B3" value="620"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="710"/>
                    <measurement group_id="B2" value="707"/>
                    <measurement group_id="B3" value="1417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Ethnicity</description>
          <population>full analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispany or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="157"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="646"/>
                    <measurement group_id="B2" value="661"/>
                    <measurement group_id="B3" value="1307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="219"/>
                    <measurement group_id="B2" value="222"/>
                    <measurement group_id="B3" value="441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Race</description>
          <population>full analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="743"/>
                    <measurement group_id="B2" value="735"/>
                    <measurement group_id="B3" value="1478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="157"/>
                    <measurement group_id="B3" value="293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Failure on the Composite of Treated Biopsy-proven Acute Rejection (tBPAR) or Estimated Glomerular Filtration Rate (eGFR) &lt; 50 mL/Min/1.73m2.</title>
        <description>Incidence of failure on the composite of treated biopsy-proven acute rejection (tBPAR) or estimated glomerular filtration rate (eGFR) &lt; 50 mL/min/1.73m2.</description>
        <time_frame>Month 12 is Primary, Month 24 secondary</time_frame>
        <population>full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>EVR+rCNI</title>
            <description>Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)</description>
          </group>
          <group group_id="O2">
            <title>MPA+sCNI</title>
            <description>Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Failure on the Composite of Treated Biopsy-proven Acute Rejection (tBPAR) or Estimated Glomerular Filtration Rate (eGFR) &lt; 50 mL/Min/1.73m2.</title>
          <description>Incidence of failure on the composite of treated biopsy-proven acute rejection (tBPAR) or estimated glomerular filtration rate (eGFR) &lt; 50 mL/min/1.73m2.</description>
          <population>full analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1022"/>
                <count group_id="O2" value="1015"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="489"/>
                    <measurement group_id="O2" value="456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="489"/>
                    <measurement group_id="O2" value="443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>calculated at month 12</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>p vale for non inferiority margin is 10 %</non_inferiority_desc>
            <p_value>0.001</p_value>
            <method>Logistic Regression Model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>7.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Failure on the Composite of (Treated Biopsy Proven Acute Rejection (tBPAR), Graft Loss or Death</title>
        <description>Incidence of failure on the composite of (treated biopsy proven acute rejection (tBPAR), graft loss or death</description>
        <time_frame>Month 12 and 24</time_frame>
        <population>full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>EVR+rCNI</title>
            <description>Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)</description>
          </group>
          <group group_id="O2">
            <title>MPA+sCNI</title>
            <description>Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Failure on the Composite of (Treated Biopsy Proven Acute Rejection (tBPAR), Graft Loss or Death</title>
          <description>Incidence of failure on the composite of (treated biopsy proven acute rejection (tBPAR), graft loss or death</description>
          <population>full analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1022"/>
                <count group_id="O2" value="1015"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169"/>
                    <measurement group_id="O2" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Failure on the Composite Endpoint of tBPAR, Graft Loss, Death or eGFR &lt; 50 mL/Min/1.73m2</title>
        <description>Incidence of failure on the composite endpoint of tBPAR, graft loss, death or eGFR &lt; 50 mL/min/1.73m2</description>
        <time_frame>Month 12 and 24</time_frame>
        <population>full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>EVR+rCNI</title>
            <description>Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)</description>
          </group>
          <group group_id="O2">
            <title>MPA+sCNI</title>
            <description>Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Failure on the Composite Endpoint of tBPAR, Graft Loss, Death or eGFR &lt; 50 mL/Min/1.73m2</title>
          <description>Incidence of failure on the composite endpoint of tBPAR, graft loss, death or eGFR &lt; 50 mL/min/1.73m2</description>
          <population>full analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1022"/>
                <count group_id="O2" value="1015"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="497"/>
                    <measurement group_id="O2" value="466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="497"/>
                    <measurement group_id="O2" value="457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Failure on the Composite Endpoint of Graft Loss or Death.</title>
        <description>Incidence of failure on the composite endpoint of graft loss or death.</description>
        <time_frame>Month 12 and 24</time_frame>
        <population>full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>EVR+rCNI</title>
            <description>Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)</description>
          </group>
          <group group_id="O2">
            <title>MPA+sCNI</title>
            <description>Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Failure on the Composite Endpoint of Graft Loss or Death.</title>
          <description>Incidence of failure on the composite endpoint of graft loss or death.</description>
          <population>full analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1022"/>
                <count group_id="O2" value="1015"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Death, Graft Loss, tBPAR, BPAR, tAR, AR and Humoral Rejection</title>
        <description>Incidence of death, graft loss, tBPAR (treated biopsy proven acute rejection), BPAR (biopsy proven acute rejection), tAR (treated acute rejection), AR (acute rejection) and humoral rejection (aAMR : active antibody mediated rejection and cAMR: chronic antibody mediated rejection)</description>
        <time_frame>Month 12 and 24</time_frame>
        <population>full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>EVR+rCNI</title>
            <description>Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)</description>
          </group>
          <group group_id="O2">
            <title>MPA+sCNI</title>
            <description>Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Death, Graft Loss, tBPAR, BPAR, tAR, AR and Humoral Rejection</title>
          <description>Incidence of death, graft loss, tBPAR (treated biopsy proven acute rejection), BPAR (biopsy proven acute rejection), tAR (treated acute rejection), AR (acute rejection) and humoral rejection (aAMR : active antibody mediated rejection and cAMR: chronic antibody mediated rejection)</description>
          <population>full analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1022"/>
                <count group_id="O2" value="1015"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>deaths month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>deaths month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>graft loss month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>graft loss month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>tBPAR month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                    <measurement group_id="O2" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>tBPAR month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118"/>
                    <measurement group_id="O2" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BPAR month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BPAR month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                    <measurement group_id="O2" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>tAR month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129"/>
                    <measurement group_id="O2" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>tAR month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                    <measurement group_id="O2" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AR month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                    <measurement group_id="O2" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AR month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167"/>
                    <measurement group_id="O2" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>aAMR month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>aAMR month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cAMR month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cAMR month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of eGFR &lt; 50 mL/Min/1.73m2</title>
        <description>Incidence of eGFR &lt; 50 mL/min/1.73m2</description>
        <time_frame>Month 12 and 24</time_frame>
        <population>full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>EVR+rCNI</title>
            <description>Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)</description>
          </group>
          <group group_id="O2">
            <title>MPA+sCNI</title>
            <description>Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of eGFR &lt; 50 mL/Min/1.73m2</title>
          <description>Incidence of eGFR &lt; 50 mL/min/1.73m2</description>
          <population>full analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1022"/>
                <count group_id="O2" value="1015"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="456"/>
                    <measurement group_id="O2" value="424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="474"/>
                    <measurement group_id="O2" value="423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Allograft Function : Mean Estimated Glomerular Filtration Rate, eGFR</title>
        <description>Renal allograft function : mean estimated glomerular filtration rate, eGFR</description>
        <time_frame>Baseline (week 4), Month 12 and 24</time_frame>
        <population>full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>EVR+rCNI</title>
            <description>Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)</description>
          </group>
          <group group_id="O2">
            <title>MPA+sCNI</title>
            <description>Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Allograft Function : Mean Estimated Glomerular Filtration Rate, eGFR</title>
          <description>Renal allograft function : mean estimated glomerular filtration rate, eGFR</description>
          <population>full analysis set</population>
          <units>mL/min/1.73m2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1022"/>
                <count group_id="O2" value="1015"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline (week 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.13" spread="0.765"/>
                    <measurement group_id="O2" value="52.25" spread="0.684"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.29" spread="0.698"/>
                    <measurement group_id="O2" value="54.49" spread="0.667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.63" spread="0.744"/>
                    <measurement group_id="O2" value="54.91" spread="0.719"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evolution of Renal Function, as eGFR, Over Time by Slope Analysis.</title>
        <description>Rate of change of renal function, as eGFR, calculated using MDRD4 formula (Coresh, 2003) and adjusted by covariates.</description>
        <time_frame>Month 12 and 24</time_frame>
        <population>full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>EVR+rCNI</title>
            <description>Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)</description>
          </group>
          <group group_id="O2">
            <title>MPA+sCNI</title>
            <description>Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).</description>
          </group>
        </group_list>
        <measure>
          <title>Evolution of Renal Function, as eGFR, Over Time by Slope Analysis.</title>
          <description>Rate of change of renal function, as eGFR, calculated using MDRD4 formula (Coresh, 2003) and adjusted by covariates.</description>
          <population>full analysis set</population>
          <units>mL / min / 1.73m2 / day</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1022"/>
                <count group_id="O2" value="1015"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" spread="0.0008"/>
                    <measurement group_id="O2" value="0.0047" spread="0.0008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Function Assessed by Creatinine Lab Values</title>
        <description>Mean Renal function as assessed in clinical practice, by ceatinine values. Analysis is done without considering missing values for analysis.</description>
        <time_frame>Month 12 and 24</time_frame>
        <population>full analysis set with measure</population>
        <group_list>
          <group group_id="O1">
            <title>EVR+rCNI</title>
            <description>Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)</description>
          </group>
          <group group_id="O2">
            <title>MPA+sCNI</title>
            <description>Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Function Assessed by Creatinine Lab Values</title>
          <description>Mean Renal function as assessed in clinical practice, by ceatinine values. Analysis is done without considering missing values for analysis.</description>
          <population>full analysis set with measure</population>
          <units>micromol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1022"/>
                <count group_id="O2" value="1015"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>screening baseline (creatinine, micromol/L)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="448"/>
                    <count group_id="O2" value="498"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="590.1" spread="262.78"/>
                    <measurement group_id="O2" value="601.8" spread="265.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 12 (creatinine, micromol/L)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="742"/>
                    <count group_id="O2" value="816"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129.8" spread="49.12"/>
                    <measurement group_id="O2" value="128.6" spread="50.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 24 (creatinine, micromol/L)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="640"/>
                    <count group_id="O2" value="719"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.1" spread="53.54"/>
                    <measurement group_id="O2" value="127.6" spread="52.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Function by Alternative Formulae (e.g. CKD-EPI). eGFR Values Reported</title>
        <description>Mean Renal function as used in clinical practice, using different formula for calculation of renal function than MDRD4 (our primary efficacy parameter), and other alternate formulae (e.g. CKD-EPI). Analysis is done without considering missing values for analysis.</description>
        <time_frame>Month 12 and 24</time_frame>
        <population>full analysis set with measure</population>
        <group_list>
          <group group_id="O1">
            <title>EVR+rCNI</title>
            <description>Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)</description>
          </group>
          <group group_id="O2">
            <title>MPA+sCNI</title>
            <description>Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Function by Alternative Formulae (e.g. CKD-EPI). eGFR Values Reported</title>
          <description>Mean Renal function as used in clinical practice, using different formula for calculation of renal function than MDRD4 (our primary efficacy parameter), and other alternate formulae (e.g. CKD-EPI). Analysis is done without considering missing values for analysis.</description>
          <population>full analysis set with measure</population>
          <units>mL/min/1.73m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1022"/>
                <count group_id="O2" value="1015"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>eGFR (Hoek) baseline (mL/min/1.73m2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="443"/>
                    <count group_id="O2" value="493"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.38" spread="14.296"/>
                    <measurement group_id="O2" value="20.10" spread="12.408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>eGFR (Hoek) month 12 (mL/min/1.73m2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="734"/>
                    <count group_id="O2" value="801"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.08" spread="14.430"/>
                    <measurement group_id="O2" value="52.00" spread="14.533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>eGFR (Hoek) month 24 (mL/min/1.73m2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="641"/>
                    <count group_id="O2" value="702"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.86" spread="14.604"/>
                    <measurement group_id="O2" value="52.75" spread="15.406"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>eGFR (MDRD4) baseline (mL/min/1.73m2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="448"/>
                    <count group_id="O2" value="498"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.79" spread="8.697"/>
                    <measurement group_id="O2" value="11.56" spread="8.853"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>eGFR (MDRD4) month 12 (mL/min/1.73m2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="742"/>
                    <count group_id="O2" value="816"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.59" spread="19.685"/>
                    <measurement group_id="O2" value="57.58" spread="18.768"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>eGFR (MDRD4) month 24 (mL/min/1.73m2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="640"/>
                    <count group_id="O2" value="719"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.07" spread="20.168"/>
                    <measurement group_id="O2" value="58.68" spread="19.541"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>eGFR-CKDEPI baseline (mL/min/1.73m2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="448"/>
                    <count group_id="O2" value="498"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.29" spread="9.094"/>
                    <measurement group_id="O2" value="11.05" spread="9.195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>eGFR-CKDEPI month 12(mL/min/1.73m2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="742"/>
                    <count group_id="O2" value="816"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.83" spread="20.686"/>
                    <measurement group_id="O2" value="58.75" spread="19.757"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>eGFR-CKDEPI month 24 (mL/min/1.73m2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="640"/>
                    <count group_id="O2" value="719"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.39" spread="21.077"/>
                    <measurement group_id="O2" value="59.95" spread="20.652"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adverse Events, Serious Adverse Events and Adverse Events Leading to Study Regimen Discontinuation.</title>
        <description>Incidence of adverse events, serious adverse events and adverse events leading to study regimen discontinuation.</description>
        <time_frame>Month 24</time_frame>
        <population>safety set 24 months analysis</population>
        <group_list>
          <group group_id="O1">
            <title>EVR+rCNI</title>
            <description>Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)</description>
          </group>
          <group group_id="O2">
            <title>MPA+sCNI</title>
            <description>Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events, Serious Adverse Events and Adverse Events Leading to Study Regimen Discontinuation.</title>
          <description>Incidence of adverse events, serious adverse events and adverse events leading to study regimen discontinuation.</description>
          <population>safety set 24 months analysis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1014"/>
                <count group_id="O2" value="1012"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276"/>
                    <measurement group_id="O2" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Cytomegalovirus and BK Virus, New Onset Diabetes Mellitus, Chronic Kidney Disease With Associated Proteinuria and Calcineurin Inhibitor Associated Adverse Events.</title>
        <description>Incidence of cytomegalovirus and BK virus, new onset diabetes mellitus, chronic kidney disease with associated proteinuria and calcineurin inhibitor associated adverse events.</description>
        <time_frame>Month 24</time_frame>
        <population>safety set</population>
        <group_list>
          <group group_id="O1">
            <title>EVR+rCNI</title>
            <description>Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)</description>
          </group>
          <group group_id="O2">
            <title>MPA+sCNI</title>
            <description>Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Cytomegalovirus and BK Virus, New Onset Diabetes Mellitus, Chronic Kidney Disease With Associated Proteinuria and Calcineurin Inhibitor Associated Adverse Events.</title>
          <description>Incidence of cytomegalovirus and BK virus, new onset diabetes mellitus, chronic kidney disease with associated proteinuria and calcineurin inhibitor associated adverse events.</description>
          <population>safety set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1014"/>
                <count group_id="O2" value="1012"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>clinical signs of CMV infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any BKV infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>new onset of diabetes mellitus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144"/>
                    <measurement group_id="O2" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at least one event of interest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="871"/>
                    <measurement group_id="O2" value="764"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Protein and Albumin Excretion by Treatment Estimated by Urinary Protein/Creatinine and Urinary Albumin/Creatinine Ratios.</title>
        <description>Mean urinary protein and albumin excretion by treatment estimated by mean urinary protein/creatinine and urinary albumin/creatinine ratios.</description>
        <time_frame>Baseline, Month 12 and 24</time_frame>
        <population>safety set with measure</population>
        <group_list>
          <group group_id="O1">
            <title>EVR+rCNI</title>
            <description>Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)</description>
          </group>
          <group group_id="O2">
            <title>MPA+sCNI</title>
            <description>Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Protein and Albumin Excretion by Treatment Estimated by Urinary Protein/Creatinine and Urinary Albumin/Creatinine Ratios.</title>
          <description>Mean urinary protein and albumin excretion by treatment estimated by mean urinary protein/creatinine and urinary albumin/creatinine ratios.</description>
          <population>safety set with measure</population>
          <units>mg/g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1014"/>
                <count group_id="O2" value="1012"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>albumine /creatinine ratio baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1019.75" spread="2737.96"/>
                    <measurement group_id="O2" value="646.111" spread="799.234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>albumine /creatinine ratio month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="729"/>
                    <count group_id="O2" value="794"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150.061" spread="482.394"/>
                    <measurement group_id="O2" value="111.322" spread="444.631"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>albumine /creatinine ratio month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="633"/>
                    <count group_id="O2" value="708"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149.049" spread="464.470"/>
                    <measurement group_id="O2" value="116.618" spread="433.392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>protein /creatinine ratio baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1648.10" spread="3768.22"/>
                    <measurement group_id="O2" value="1142.59" spread="1003.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>protein /creatinine ratio month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="729"/>
                    <count group_id="O2" value="794"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="298.557" spread="642.103"/>
                    <measurement group_id="O2" value="234.698" spread="583.632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>protein /creatinine ratio month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="633"/>
                    <count group_id="O2" value="708"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="290.242" spread="588.119"/>
                    <measurement group_id="O2" value="233.009" spread="524.383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Major Cardiovascular Events.</title>
        <description>Incidence of major cardiovascular events by Preferred Term</description>
        <time_frame>Month 24</time_frame>
        <population>safety set</population>
        <group_list>
          <group group_id="O1">
            <title>EVR+rCNI</title>
            <description>Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)</description>
          </group>
          <group group_id="O2">
            <title>MPA+sCNI</title>
            <description>Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Major Cardiovascular Events.</title>
          <description>Incidence of major cardiovascular events by Preferred Term</description>
          <population>safety set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1014"/>
                <count group_id="O2" value="1012"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Malignancies.</title>
        <description>Incidence of malignancies.</description>
        <time_frame>Month 24</time_frame>
        <population>safety set</population>
        <group_list>
          <group group_id="O1">
            <title>EVR+rCNI</title>
            <description>Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)</description>
          </group>
          <group group_id="O2">
            <title>MPA+sCNI</title>
            <description>Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Malignancies.</title>
          <description>Incidence of malignancies.</description>
          <population>safety set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1014"/>
                <count group_id="O2" value="1012"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Failure on the Composite of Treated Biopsy-proven Acute Rejection (tBPAR) or Estimated Glomerular Filtration Rate (eGFR) &lt; 50 mL/Min/1.73m2 Among Compliant Subjects.</title>
        <description>Incidence of failure on the composite of treated biopsy-proven acute rejection (tBPAR) or estimated glomerular filtration rate (eGFR) &lt; 50 mL/min/1.73m2 among compliant subjects.</description>
        <time_frame>Month 12 and 24</time_frame>
        <population>compliance set</population>
        <group_list>
          <group group_id="O1">
            <title>EVR+rCNI</title>
            <description>Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)</description>
          </group>
          <group group_id="O2">
            <title>MPA+sCNI</title>
            <description>Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Failure on the Composite of Treated Biopsy-proven Acute Rejection (tBPAR) or Estimated Glomerular Filtration Rate (eGFR) &lt; 50 mL/Min/1.73m2 Among Compliant Subjects.</title>
          <description>Incidence of failure on the composite of treated biopsy-proven acute rejection (tBPAR) or estimated glomerular filtration rate (eGFR) &lt; 50 mL/min/1.73m2 among compliant subjects.</description>
          <population>compliance set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence tBPAR (Treated Biopsy-proven Acute Rejection) by Severity and Time to Event (Participants)</title>
        <description>Incidence tBPAR, defined as any condition where the subject received anti-rejection treatment and was histologically diagnosed as acute rejection (according to the Banff 2009 criteria), by severity (grade IA, IB, IIA, IIB, III) and time to event. Grades for T-cell mediated rejection, with increasing severity:
Type IA - Significant interstitial infiltration (&gt; 25% of parenchyma) and foci of moderate tubulitis (&gt; 4 mononuclear cells/tubular cross section or group of 10 tubular cells).
Type IB - Significant interstitial infiltration (&gt; 25% of parenchyma) and foci of severe tubulitis (&gt; 10 mononuclear cells/tubular cross section or group of 10 tubular cells).
Type IIA - Mild to moderate intimal arteritis
Type IIB - Severe intimal arteritis comprising &gt; 25% of the lumenal area
Type III - Transmural (full vessel wall thickness) arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells (with accompanying lymphocytic inflammation)</description>
        <time_frame>Month 12 and 24</time_frame>
        <population>full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>EVR+rCNI</title>
            <description>Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)</description>
          </group>
          <group group_id="O2">
            <title>MPA+sCNI</title>
            <description>Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence tBPAR (Treated Biopsy-proven Acute Rejection) by Severity and Time to Event (Participants)</title>
          <description>Incidence tBPAR, defined as any condition where the subject received anti-rejection treatment and was histologically diagnosed as acute rejection (according to the Banff 2009 criteria), by severity (grade IA, IB, IIA, IIB, III) and time to event. Grades for T-cell mediated rejection, with increasing severity:
Type IA - Significant interstitial infiltration (&gt; 25% of parenchyma) and foci of moderate tubulitis (&gt; 4 mononuclear cells/tubular cross section or group of 10 tubular cells).
Type IB - Significant interstitial infiltration (&gt; 25% of parenchyma) and foci of severe tubulitis (&gt; 10 mononuclear cells/tubular cross section or group of 10 tubular cells).
Type IIA - Mild to moderate intimal arteritis
Type IIB - Severe intimal arteritis comprising &gt; 25% of the lumenal area
Type III - Transmural (full vessel wall thickness) arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells (with accompanying lymphocytic inflammation)</description>
          <population>full analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1022"/>
                <count group_id="O2" value="1015"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patient's maximum tBPAR grade : no grade (missing)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient's maximum tBPAR grade : grade IA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient's maximum tBPAR grade : grade IB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient's maximum tBPAR grade : grade IIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient's maximum tBPAR grade : grade IIB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient's maximum tBPAR grade : grade III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence tBPAR (Treated Biopsy-proven Acute Rejection) by Severity and Time to Event (Events)</title>
        <description>Incidence tBPAR, defined as any condition where the subject received anti-rejection treatment and was histologically diagnosed as acute rejection (according to the Banff 2009 criteria), by severity (grade IA, IB, IIA, IIB, III) and time to event. Grades for T-cell mediated rejection, with increasing severity:
Type IA - Significant interstitial infiltration (&gt; 25% of parenchyma) and foci of moderate tubulitis (&gt; 4 mononuclear cells/tubular cross section or group of 10 tubular cells).
Type IB - Significant interstitial infiltration (&gt; 25% of parenchyma) and foci of severe tubulitis (&gt; 10 mononuclear cells/tubular cross section or group of 10 tubular cells).
Type IIA - Mild to moderate intimal arteritis
Type IIB - Severe intimal arteritis comprising &gt; 25% of the lumenal area
Type III - Transmural (full vessel wall thickness) arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells (with accompanying lymphocytic inflammation)</description>
        <time_frame>Month 12 and 24</time_frame>
        <population>full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>EVR+rCNI</title>
            <description>Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)</description>
          </group>
          <group group_id="O2">
            <title>MPA+sCNI</title>
            <description>Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence tBPAR (Treated Biopsy-proven Acute Rejection) by Severity and Time to Event (Events)</title>
          <description>Incidence tBPAR, defined as any condition where the subject received anti-rejection treatment and was histologically diagnosed as acute rejection (according to the Banff 2009 criteria), by severity (grade IA, IB, IIA, IIB, III) and time to event. Grades for T-cell mediated rejection, with increasing severity:
Type IA - Significant interstitial infiltration (&gt; 25% of parenchyma) and foci of moderate tubulitis (&gt; 4 mononuclear cells/tubular cross section or group of 10 tubular cells).
Type IB - Significant interstitial infiltration (&gt; 25% of parenchyma) and foci of severe tubulitis (&gt; 10 mononuclear cells/tubular cross section or group of 10 tubular cells).
Type IIA - Mild to moderate intimal arteritis
Type IIB - Severe intimal arteritis comprising &gt; 25% of the lumenal area
Type III - Transmural (full vessel wall thickness) arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells (with accompanying lymphocytic inflammation)</description>
          <population>full analysis set</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1022"/>
                <count group_id="O2" value="1015"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>overall number of tBPAR regardless of grade</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>number of tBPAR regardless of grade days 1-90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>number of tBPAR regardless of grade days 91-180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>number of tBPAR regardless of grade days 181-360</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>number of tBPAR regardless of grade days 361-540</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>number of tBPAR regardless of grade days 541-720</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>number of tBPAR regardless of grade days 721-810</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of tBPAR (Treated Biopsy-proven Acute Rejection) Excluding Grade IA Rejections</title>
        <description>Incidence of tBPAR, defined as any condition where the subject received anti-rejection treatment and was histologically diagnosed as acute rejection (according to the Banff 2009 criteria), excluding grade IA rejections. Grades for T-cell mediated rejection, with increasing severity:
Type IA - Significant interstitial infiltration (&gt; 25% of parenchyma) and foci of moderate tubulitis (&gt; 4 mononuclear cells/tubular cross section or group of 10 tubular cells).
Type IB - Significant interstitial infiltration (&gt; 25% of parenchyma) and foci of severe tubulitis (&gt; 10 mononuclear cells/tubular cross section or group of 10 tubular cells).
Type IIA - Mild to moderate intimal arteritis
Type IIB - Severe intimal arteritis comprising &gt; 25% of the lumenal area
Type III - Transmural (full vessel wall thickness) arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells (with accompanying lymphocytic inflammation)</description>
        <time_frame>Month 12 and 24</time_frame>
        <population>full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>EVR+rCNI</title>
            <description>Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)</description>
          </group>
          <group group_id="O2">
            <title>MPA+sCNI</title>
            <description>Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of tBPAR (Treated Biopsy-proven Acute Rejection) Excluding Grade IA Rejections</title>
          <description>Incidence of tBPAR, defined as any condition where the subject received anti-rejection treatment and was histologically diagnosed as acute rejection (according to the Banff 2009 criteria), excluding grade IA rejections. Grades for T-cell mediated rejection, with increasing severity:
Type IA - Significant interstitial infiltration (&gt; 25% of parenchyma) and foci of moderate tubulitis (&gt; 4 mononuclear cells/tubular cross section or group of 10 tubular cells).
Type IB - Significant interstitial infiltration (&gt; 25% of parenchyma) and foci of severe tubulitis (&gt; 10 mononuclear cells/tubular cross section or group of 10 tubular cells).
Type IIA - Mild to moderate intimal arteritis
Type IIB - Severe intimal arteritis comprising &gt; 25% of the lumenal area
Type III - Transmural (full vessel wall thickness) arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells (with accompanying lymphocytic inflammation)</description>
          <population>full analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1022"/>
                <count group_id="O2" value="1015"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Composite of tBPAR (Treated Biopsy-proven Acute Rejection)or eGRF&lt;50 mL/Min/1.73m2 by Subgroup</title>
        <description>Incidence of composite of tBPAR or eGRF&lt;50 mL/min/1.73m2 by subgroup</description>
        <time_frame>Month 12 and 24</time_frame>
        <population>full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>EVR+rCNI</title>
            <description>Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)</description>
          </group>
          <group group_id="O2">
            <title>MPA+sCNI</title>
            <description>Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Composite of tBPAR (Treated Biopsy-proven Acute Rejection)or eGRF&lt;50 mL/Min/1.73m2 by Subgroup</title>
          <description>Incidence of composite of tBPAR or eGRF&lt;50 mL/min/1.73m2 by subgroup</description>
          <population>full analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1022"/>
                <count group_id="O2" value="1015"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="489"/>
                    <measurement group_id="O2" value="456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="489"/>
                    <measurement group_id="O2" value="443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of tBPAR (Excluding Grade IA Rejections) or GFR&lt;50 mL/Min/1.73m2</title>
        <description>Incidence of tBPAR (excluding grade IA rejections) or GFR&lt;50 mL/min/1.73m2</description>
        <time_frame>Month 12 and 24</time_frame>
        <population>full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>EVR+rCNI</title>
            <description>Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)</description>
          </group>
          <group group_id="O2">
            <title>MPA+sCNI</title>
            <description>Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of tBPAR (Excluding Grade IA Rejections) or GFR&lt;50 mL/Min/1.73m2</title>
          <description>Incidence of tBPAR (excluding grade IA rejections) or GFR&lt;50 mL/min/1.73m2</description>
          <population>full analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1022"/>
                <count group_id="O2" value="1015"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="475"/>
                    <measurement group_id="O2" value="441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="475"/>
                    <measurement group_id="O2" value="426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Failure on the Composite of (Treated Biopsy Proven Acute Rejection (tBPAR), Graft Loss or Death or Loss to Follow-up</title>
        <description>Incidence of failure on the composite of (treated biopsy proven acute rejection (tBPAR), graft loss or death or loss to follow-up</description>
        <time_frame>Month 12 and 24</time_frame>
        <population>full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>EVR+rCNI</title>
            <description>Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)</description>
          </group>
          <group group_id="O2">
            <title>MPA+sCNI</title>
            <description>Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Failure on the Composite of (Treated Biopsy Proven Acute Rejection (tBPAR), Graft Loss or Death or Loss to Follow-up</title>
          <description>Incidence of failure on the composite of (treated biopsy proven acute rejection (tBPAR), graft loss or death or loss to follow-up</description>
          <population>full analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1022"/>
                <count group_id="O2" value="1015"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181"/>
                    <measurement group_id="O2" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                    <measurement group_id="O2" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All Adverse events are reported in this record from First Patient First Treatment until Last Patient Last Visit up to approximately 4 years.</time_frame>
      <desc>treatment emergent AE / SAE . Consistent with EudraCT disclosure specifications, Novartis has reported under the Serious adverse events fields &quot;number of deaths resulting from adverse events&quot; all those deaths, resulting from serious adverse events that are deemed to be causally related to treatment by the investigator.</desc>
      <group_list>
        <group group_id="E1">
          <title>Everolimus Plus@Reduced CNI</title>
          <description>Everolimus plus@reduced CNI</description>
        </group>
        <group group_id="E2">
          <title>MPA Plus Standard@CNI</title>
          <description>MPA plus standard@CNI</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (20.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="593" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="613" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Agranulocytosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Atypical haemolytic uraemic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Bone marrow failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Granulocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Haemolysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Haemolytic uraemic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Lymphatic obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Nephrogenic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Polycythaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Sickle cell anaemia with crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Splenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Thrombotic microangiopathy</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Cardiac asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Cardiac dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Cardiorenal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Left ventricular hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pericarditis constrictive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pulseless electrical activity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Ventricular tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous malformation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Congenital cystic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Congenital megaureter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Tracheo-oesophageal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Mastoid effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism tertiary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Optic ischaemic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Abdominal wall haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Acute abdomen</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Anal polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Anogenital dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Barrett's oesophagus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Diabetic gastroparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Duodenal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Encapsulating peritoneal sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Gastrointestinal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hernial eventration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Intra-abdominal fluid collection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Lumbar hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Oesophageal achalasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Oesophageal spasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Salivary gland enlargement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Volvulus of small bowel</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Gait inability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Ill-defined disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Medical device site discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Medical device site inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Microlithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Suprapubic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Biliary dilatation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hepatocellular injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Perforation bile duct</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Chronic allograft nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Immunosuppression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Kidney transplant rejection</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Renal transplant failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Transplant rejection</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Actinomycosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Adenoviral haemorrhagic cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Adenovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Asymptomatic bacteriuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>BK virus infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Bacterial diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Bacterial prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Bacterial pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Bacteriuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Blister infected</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Candiduria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Chest wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Chronic tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Corona virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Cryptococcosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Cystitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Dermatophytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Disseminated tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Enterococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Enterococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Enterocolitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Escherichia pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Fungal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Gastroenteritis clostridial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Gastroenteritis cryptosporidial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>HIV infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Haematoma infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hepatic cyst infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hepatitis E</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hepatitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Herpes simplex pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Herpes zoster disseminated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Ileal gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Infected lymphocele</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Infected seroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Intestinal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Klebsiella bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Medical device site cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Medical device site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Meningitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Meningitis cryptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Nocardiosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Osteomyelitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Parvovirus B19 infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Perinephric abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pneumonia cryptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pneumonia cytomegaloviral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pneumonia fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pneumonia haemophilus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Polyomavirus-associated nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Postoperative abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pseudomonal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pseudomonal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pyuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Renal cyst infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Renal graft infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Rhinovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Sinusitis fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Systemic candida</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Tonsillitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Transplant abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Tuberculosis gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Urinary tract infection enterococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Urinary tract infection fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Viral diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Viral myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Wound abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Anaemia postoperative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Anaesthetic complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Anastomotic haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Aponeurosis contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Arterial injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Avulsion fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Complications of transplant surgery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Complications of transplanted kidney</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Coronary bypass stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Delayed graft function</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Graft complication</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Graft haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Graft loss</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Graft thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Incision site complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Musculoskeletal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Peripheral arterial reocclusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Perirenal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Post procedural discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Post procedural haematuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Post procedural persistent drain fluid</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Post procedural urine leak</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Postoperative fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Postoperative hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Renal lymphocele</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Renal transplant torsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Scar</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Scrotal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Shunt aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Shunt stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Stress fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Subcutaneous haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Transplant dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Transplant failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Transplantation complication</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Traumatic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Ureteric anastomosis complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Urinary anastomotic leak</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Vaccination complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Vascular graft complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Vascular graft stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Vascular graft thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Wound decomposition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Wound secretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Anticoagulation drug level above therapeutic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Biopsy kidney</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Blood creatine increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Blood creatinine abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Catheterisation cardiac</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Ejection fraction abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T wave inversion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Haptoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Immunosuppressant drug level increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Inflammatory marker increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Norovirus test positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Occult blood positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Polyomavirus test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Calciphylaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hypervolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Intervertebral disc space narrowing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Myalgia intercostal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pubic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Sacroiliitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma pancreas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Benign gastrointestinal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of thyroid gland</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Benign pancreatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Bronchioloalveolar carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Cerebral haemangioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Clear cell renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Epstein-Barr virus associated lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Leydig cell tumour of the testis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Lymphoproliferative disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of pleura metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Metastases to peritoneum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Metastatic squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Monoclonal gammopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Papillary tumour of renal pelvis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Plasmacytoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Polycythaemia vera</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Post transplant lymphoproliferative disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Salivary gland cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Testicular neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Tumour of ampulla of Vater</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Autoimmune encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Central nervous system lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Cerebellar stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hyponatraemic seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Myelitis transverse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Neurotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Transverse sinus thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Visual field defect</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Cephalhaematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Device leakage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute psychosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hallucination, visual</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Post-traumatic stress disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Anuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Bladder neck obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Bladder obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Bladder perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Cystitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>End stage renal disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Focal segmental glomerulosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis membranoproliferative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis membranous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Glycosuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Haemorrhage urinary tract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hydroureter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hypertonic bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>IgM nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Ischaemic nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Leukocyturia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Mesangioproliferative glomerulonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Nephropathy toxic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Obstructive nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pelvi-ureteric obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Perinephric collection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pyelocaliectasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Renal artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Renal artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Renal artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Renal cortical necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Renal cyst haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Renal cyst ruptured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Renal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Renal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Renal necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Renal tubular atrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Renal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Ureteric dilatation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Urethral obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Urge incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Urinary bladder haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Urinary bladder polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Urinary fistula</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Urinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Vesicoureteric reflux</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Scrotal oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Testicular oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Asthmatic crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pulmonary artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Capillaritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Neuropathic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Peau d'orange</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Skin necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Skin oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Loss of personal independence in daily activities</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Walking disability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous fistula operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Orchidectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Accelerated hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Aortic perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Arterial stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Arterial thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Embolism venous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Lymphorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Malignant hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pelvic venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Varicose ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Venous stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (20.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="951" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="942" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="227" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="238" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="194" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Polycythaemia</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="104" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="245" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="242" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="242" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="318" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="191" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="225" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="140" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="347" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="244" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="132" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BK virus infection</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="101" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="117" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="102" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="219" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="249" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Complications of transplanted kidney</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Incision site pain</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="141" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="133" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="120" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="140" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="144" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="164" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="184" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="135" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="148" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="134" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="168" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="190" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="167" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="133" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="113" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="145" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="138" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="101" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="131" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="102" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="240" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="230" subjects_at_risk="1012"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="1014"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="1012"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharma</organization>
      <phone>8627788300</phone>
      <email>Novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

